IPO - CapsoVision, Inc

Form Type: S-1

Filing Date: 2025-05-09

Corporate Action: Ipo

Type: New

Accession Number: 000119312525116894

Filing Summary: CapsoVision, Inc. is filing for an initial public offering (IPO) of common stock, intending to offer shares in a range between a specified price per share, with the exact amount to be determined later. As an emerging growth and smaller reporting company, CapsoVision anticipates a public market establishment for its shares following the completion of the registration statement with the SEC. The company's products, including the CapsoCam Plus and upcoming CapsoCam Colon, are focused on enhancing gastrointestinal (GI) diagnostic capabilities through advanced imaging technology and artificial intelligence. Their business aims to improve the detection of small bowel abnormalities and colorectal polyps, which are critical for preventing more serious health conditions. The preliminary prospectus indicates that there is significant market potential, especially within the capsule endoscopy market, which is projected to grow significantly by 2030. The company highlights its commitment to innovation, regulatory compliance, and evolving their product offerings while also indicating risk factors tied to its growth and market competition.

Form Type: DRS/A

Filing Date: 2025-03-14

Corporate Action: Ipo

Type: New

Accession Number: 000095012325003072

Filing Summary: CapsoVision, Inc. is preparing for its initial public offering (IPO) by filing a registration statement with the SEC. This document details the offering of shares of common stock valued at $0.001 per share, with the initial public offering price expected to range between an unlisted minimum and maximum amount. The registration indicates that there has been no public market for the company's shares prior to this offering. CapsoVision, based in Saratoga, CA, focuses on advanced imaging and AI technologies for gastrointestinal applications, primarily through its CapsoCam Plus product. The company targets the U.S. market for its capsule endoscopy and anticipates substantial growth driven by increasing adoption of its products in gastroenterology. The SEC filing states that CapsoVision qualifies as an emerging growth and smaller reporting company, allowing it to take advantage of reduced disclosure and reporting obligations. Furthermore, the prospectus includes a warning about the speculative nature of the investment due to the inherent risks in the market and technology sector they operate in.

Form Type: DRS

Filing Date: 2025-02-07

Corporate Action: Ipo

Type: New

Accession Number: 000095012325001205

Filing Summary: CapsoVision, Inc. is filing a draft registration statement with the SEC for an initial public offering (IPO) of common stock. This is the first public offering of CapsoVision's common stock, where they plan to offer shares at a price range yet to be defined. The common stock will be listed on the Nasdaq under the symbol 'CV'. CapsoVision specializes in advanced imaging and AI technologies related to capsule endoscopy for gastrointestinal diagnostics. They are currently an emerging growth company and have seen continuous revenue growth since establishing direct sales in the U.S. since 2020, with revenues for the years ending December 31, 2023, and 2024 reported at approximately $9.8 million, reflecting market expansion and product acceptance. They emphasize the high speculative nature of the investment due to market risks, the need for FDA clearances for future products, and the uncertainties involved in forward-looking statements about operational and financial performance.